News

The approval covers both adult and paediatric patients aged eight years and above. GSDIa is a rare genetic metabolic disorder caused by a deficiency in the enzyme required

AQPotency is accessible through Claude via the Model Context Protocol (MCP), as well as through the SandboxAQ website, with plans for listing on Google Cloud’s Marketplace. It enables

The partnership aims to progress this gene therapy using Andelyn’s AAV Curator Platform. GM2 gangliosidosis is a rare genetic disorder that leads to the progressive loss of nerve

The renewed agreement is expected to reach approximately 1,000 patients cumulatively by its conclusion. This partnership, which began in 2023, has so far provided Brukinsa to more than

The designation applies specifically to patients whose tumours contain a phosphatidylinositol 3-kinase / protein kinase B / mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway alteration. It also applies to

The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the “SLTE” ticker symbol. Following completion of the merger, the new

With this validation, the agency will begin its formal assessment of the application. The submission is supported by efficacy and safety data from the Phase III VALOR clinical

The company is evaluating spevatamig in Phase II clinical studies for various gastrointestinal cancers. Spevatamig is a bispecific antibody targeting claudin 18.2 and cluster of differentiation 47 (CD47),

The combination is intended for patients who have previously received at least one line of therapy that included both a proteasome inhibitor and an immunomodulatory agent. Zenbexus is